Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.

Donadon V, Balbi M, Mas MD, Casarin P, Zanette G.

Liver Int. 2010 May;30(5):750-8. doi: 10.1111/j.1478-3231.2010.02223.x. Epub 2010 Mar 12.

PMID:
20331505
2.

Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease.

Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C.

World J Gastroenterol. 2009 May 28;15(20):2506-11.

3.

Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.

Donadon V, Balbi M, Casarin P, Vario A, Alberti A.

World J Gastroenterol. 2008 Oct 7;14(37):5695-700.

4.

Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.

Donadon V, Balbi M, Valent F, Avogaro A.

World J Gastroenterol. 2010 Jun 28;16(24):3025-32.

5.

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.

Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY.

Gut. 2013 Apr;62(4):606-15. doi: 10.1136/gutjnl-2011-301708. Epub 2012 Jul 7.

PMID:
22773548
6.

Metformin does not improve survival in patients with hepatocellular carcinoma.

Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR.

World J Gastroenterol. 2014 Nov 14;20(42):15750-5. doi: 10.3748/wjg.v20.i42.15750.

7.

Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.

Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Sata M.

Liver Int. 2010 Mar;30(3):479-86. doi: 10.1111/j.1478-3231.2009.02191.x. Epub 2009 Dec 22.

PMID:
20040053
8.

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.

Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M.

J Clin Endocrinol Metab. 2011 Aug;96(8):2601-8. doi: 10.1210/jc.2010-2415. Epub 2011 Jul 13.

PMID:
21752887
9.

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.

Zhang H, Gao C, Fang L, Zhao HC, Yao SK.

Scand J Gastroenterol. 2013 Jan;48(1):78-87. doi: 10.3109/00365521.2012.719926. Epub 2012 Nov 9.

PMID:
23137049
10.

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.

Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC.

Am J Gastroenterol. 2012 Jan;107(1):46-52. doi: 10.1038/ajg.2011.384. Epub 2011 Nov 15.

PMID:
22085817
11.

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.

Singh S, Singh PP, Singh AG, Murad MH, Sanchez W.

Am J Gastroenterol. 2013 Jun;108(6):881-91; quiz 892. doi: 10.1038/ajg.2013.5. Epub 2013 Feb 5. Review.

PMID:
23381014
12.

A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.

Zhang JY, Dai M, Wang X, Lu WQ, Li DS, Zhang MX, Wang KJ, Dai LP, Han SG, Zhou YF, Zhuang H.

Int J Epidemiol. 1998 Aug;27(4):574-8.

PMID:
9758109
13.

Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.

Harris K, Smith L.

Ann Pharmacother. 2013 Oct;47(10):1348-52. doi: 10.1177/1060028013503108. Review.

PMID:
24259699
14.

Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia.

Chen HH, Lin MC, Muo CH, Yeh SY, Sung FC, Kao CH.

Medicine (Baltimore). 2015 Jun;94(24):e1013. doi: 10.1097/MD.0000000000001013.

15.

Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.

Wang P, Kang D, Cao W, Wang Y, Liu Z.

Diabetes Metab Res Rev. 2012 Feb;28(2):109-22. doi: 10.1002/dmrr.1291. Review.

PMID:
21898753
16.

Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.

Bosetti C, Franchi M, Nicotra F, Asciutto R, Merlino L, La Vecchia C, Corrao G.

Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):771-8. doi: 10.1002/pds.3801. Epub 2015 May 27.

PMID:
26013675
17.

Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation.

Chen TM, Lin CC, Huang PT, Wen CF.

J Gastroenterol Hepatol. 2011 May;26(5):858-65. doi: 10.1111/j.1440-1746.2011.06664.x.

PMID:
21251068
18.

Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes--National cohort of Taiwan Diabetes Study.

Li CI, Chen HJ, Lai HC, Liu CS, Lin WY, Li TC, Lin CC.

Int J Cancer. 2015 Jun 1;136(11):2668-79. doi: 10.1002/ijc.29321. Epub 2014 Dec 1.

19.

The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey.

Kawaguchi T, Kohjima M, Ichikawa T, Seike M, Ide Y, Mizuta T, Honda K, Nakao K, Nakamuta M, Sata M.

J Gastroenterol. 2015 Mar;50(3):333-41. doi: 10.1007/s00535-014-0968-5. Epub 2014 Jun 10.

PMID:
24912965
20.

Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.

Kim G, Jang SY, Han E, Lee YH, Park SY, Nam CM, Kang ES.

Int J Cancer. 2017 Feb 15;140(4):798-806. doi: 10.1002/ijc.30506. Epub 2016 Nov 16.

PMID:
27861855

Supplemental Content

Support Center